CREATE Medicines develops in vivo immune programming therapies by delivering proprietary mRNA-LNP constructs that directly engineer T cells, NK cells, and myeloid cells inside the body to enable scalable, repeat-dose, off-the-shelf immunotherapies. Its lead autoimmune program, CRT-402, is a next-generation CD19 targeted in vivo CAR-T candidate with demonstrated deep and durable B cell depletion in non-human primates and designed for repeat dosing; the company is also advancing a dual CAR CD19 x BCMA program to broaden reach across refractory autoimmune indications. In oncology, CREATE is advancing multiple programs, including MT-303, which has shown compelling early clinical responses in frontline hepatocellular carcinoma. The company reports dosing more than 50 patients across its in vivo CAR clinical programs, which it cites as the largest clinical dataset in the field. CREATE highlights integration of clinically validated CAR architectures, optimized RNA design, targeted delivery technologies, and ownership of manufacturing infrastructure as core competitive advantages. Recent leadership additions include Ron Philip as Executive Chairman and new board members from ARCH Venture Partners and Newpath Partners.

Total raised

$245M

Funding rounds

3

Latest round

Series B

Latest activity

May 2026